·
Asia Pacific insulin market is expected to reach
more than USD 10 Billion by 2018
·
Future Growth of the insulin market will be led
by greater consumption of the long acting insulin
·
Market leaders are anticipated to maintain
focus on expanding R&D facilities and distribution network in emerging
markets of China and India
Ken
Research announced its latest publication on “Asia Pacific Insulin Market
Review to 2018” which provides a comprehensive analysis of major countries and types
of insulin consumed in the region. The report covers various aspects such as
market size of Asia Pacific insulin market, segmentation on the basis of geographies
(China, India and Japan) and future outlook of the market. The report is useful
for insulin manufacturers and distributors, as well as new players venturing in
the market.
 |
| Asia Pacific insulin market |
Diabetes is spreading more rapidly in Asia Pacific than any other
region in the world. It is a perceived notion that unlike the western countries
where diabetes affects older people, in Asia Pacific, the disease is
disproportionately high in young to middle-aged adults. Insulin, the basis of
diabetes treatment has witnessed a surge in demand in the past decade. Factors
such as growing diabetic population, increasing expenditure on healthcare both
by the consumers and the government, expanding distribution network and high
scope in developing economies such as China and India poses to be potential
drivers for the insulin market in Asia Pacific region. The market registered a
CAGR of 13.9% during 2008-2013.
According to the
research report, the Asia Pacific insulin market will grow at an impressive
CAGR, thereby exceeding USD 10 billion by 2018, largely due to increasing
incidence of diabetes and rising healthcare expenditure both by the government
and the consumers.
“Although lack
of diabetes care awareness and low affordability will hinder the growth of the
insulin market in the Asia Pacific, rising disposable income of the population
and diagnosis of diabetes will cater to increasing consumption of insulin in
the region”, according to the Research Associate, Ken Research.
Key
Topics Covered in the Report:
-
Asia Pacific Insulin Market Size by Revenue
-
Market Segmentation by Geographies (China,
India, Japan)
-
Trends, Growth Drivers and Issues
-
Country wise market size and segmentation
-
Competition and Market Share
-
Future Outlook
-
Macro Economic Parameters
Key
Products Mentioned in the Report
Human Insulin
Analog Insulin
Premix Insulin
Rapid Acting Insulin
Long Acting Insulin
Companies
Covered in the Report
Novo Nordisk
Eli Lilly and Company
Sanofi Aventis
Biocon
Wockhardt
BJ Ganli Pharmaceuticals
Tonghua Dongbao
Browse and Download Report Here- http://www.kenresearch.com/healthcare/pharmaceutical-industry/asia-pacific-insulin-market-research-report/572-91.html
Related Reports:
Contact:
